NHS Halts New Gender-Affirming Hormone Referrals for Minors

NHS England has announced a suspension of new referrals for gender-affirming hormone therapy for individuals under the age of 18, citing a lack of sufficient evidence to support its use. Effective immediately, this decision means that those aged 16 and 17 will no longer be eligible for new prescriptions of hormones such as testosterone and oestrogen, which many medical professionals consider essential for the wellbeing of transgender youth.

The announcement follows recommendations from the Cass Review, a report led by paediatrician Hilary Cass that has attracted significant controversy in the UK. The review not only advocated for the suspension of hormone treatments for minors but also called for a ban on prescribing puberty blockers for transgender youth. This has led to widespread criticism from various medical organizations, including the British Medical Association and the World Association for Transgender Health (WPATH), who argue that the review failed to consider relevant research and deviated from standard practices in evaluating medical research.

Under the new directive, individuals who currently hold prescriptions for hormone replacement therapy will continue to receive their treatment, although NHS clinicians have been instructed to review these cases moving forward. According to James Palmer, the national medical director for specialised services at NHS England, the decision reflects a cautious approach to the treatment of young people. He stated, “The NHS has exercised extreme caution when considering starting young people on this treatment – in accordance with the advice from Dr Cass – and as part of this action will now be pausing any new referrals for this treatment for 16- and 17-year-olds.”

Critics of the NHS decision have voiced strong objections. Tammy Hymas, policy lead at TransActual, condemned the ban as a significant infringement on young people’s bodily autonomy. Hymas emphasized that the decision disproportionately affects transgender individuals and reflects broader systemic issues faced by this community.

The decision by NHS England has drawn attention not only within the UK but also internationally, as it raises questions about the future of transgender healthcare for minors. Many advocates fear that restricting access to gender-affirming treatments could have detrimental effects on the mental health and overall wellbeing of young transgender individuals.

As this situation unfolds, the implications of the NHS’s decision are likely to resonate throughout the healthcare community and among advocacy groups, potentially influencing policy discussions and treatment protocols in the future.